key: cord-0916514-e3pzwrup
authors: Kott, A.; Daniel, D.G.
title: P.508 COVID-19 impact on entry symptom severity in schizophrenia clinical trials – preliminary data
date: 2020-11-17
journal: Eur Neuropsychopharmacol
DOI: 10.1016/j.euroneuro.2020.09.372
sha: 56c595145412d076f921a331e40733fd518ff647
doc_id: 916514
cord_uid: e3pzwrup

nan

Changes in symptom severity and expression might occur due to increased stress, fear of illness, diminution of contact with research site and other psychiatric personnel and enforced social distancing. In the current project we intend to analyze individual symptom severity as assessed by the PANSS [1] data collected in the screening period in ongoing clinical trials in schizophrenia that started before the COVID-19 pandemic and assesses whether COVID-19 has an impact on the severity of symptoms as well as the variability of the data. Methods: Data are collected from currently ongoing schizophrenia clinical trials that started before the COVID-19 outbreak. To account for different protocol designs data collected in the screening period are analyzed separately by each clinical trial. We have arbitrarily set the date of the first confirmed COVID-19 case within each country as the reference date and treated all data collected after this date as data affected by the COVID-19 pandemic. On an item level we utilize Wilcoxon rank-sum test for equality of distributions, K-sample equality-of-medians test and Levene's robust test statistic for the equality of variances. Given the exploratory type of analysis we consider the data as potentially impacted by COVID-19 if at least one of the 'distribution' tests or the variance test with the median location estimator indicates statistical difference in the data collected after the reference date. Results: Our dataset currently consists 1254 datapoints collected in the screening period, 1086(88%) collected before and 168(12%) collected after the reference date. The plan is to increase the dataset as additional data become available. In data coming from acute studies (399 data points, 114(29%) collected after reference date) significantly higher severity was observed in the data collected after the reference date for the following items: P3, G2, G4, and G16; significantly lower severity for items P2, P4, N7, G10 and G12. Variability was increased for items N4 and G16 and decreased for items P2, P3, G2 and G10. In data coming from studies in subjects with predominantly negative symptoms (855 data points, 54(6%) collected after reference date) significantly higher severity was observed in the data collected after the reference date for items N1 and N6, and significantly lower for items P3, P4, G1 and G14. Variability was increased for item G1 and decreased for item P4. Discussion: Our preliminary analyses indicate that COVID-19 pandemic has a significant impact on a wide span of symptoms in schizophrenia clinical trial participants. Some effects, such as increase in anxiety, tension or active social avoidance, are within expectations, some, e.g. decrease in conceptual disorganization, are unexpected. The extent of possible impact on trial outcomes is yet to be determined, our limited dataset did not allow for analysis of change data at this point. We plan to increase the sample size and the spectrum of the analyses for the actual presentation as more data become available. Introduction: Late-onset psychotic illness in the elderly seems now much more common than initial studies suggested with a greater prevalence in women. The majority of bibliography available is not recent and usually study patients with an age range between 60 and 80 years old.

In elderly the focus of the clinical trials is usually dementia or depression, meanwhile psychosis is usually studied in teenagers and young adults. The onset and trajectory of a psychotic illness in the geriatric population may present itself with different characteristics and be influenced by their comorbidities.

Objectives: Describe a clinical case of a one-hundred-oneyears-old woman with a first onset of psychotic symptomology admitted through the emergency room in an inpatient geriatric psychiatric yard. Create awareness to psychotic illness in ancient people. Results: This case describes a one-hundred-one-years-old woman that lives with her daughter, she was brought to the emergency room because of irritability, aggressive behaviour towards her daughter, refusing food and medication and persecutory thoughts that started one month before. During the psychiatric observation it was possible to detect persecutory ideation towards the daughter as the patient states that she is being poisoned by her daughter trough incorrect administration of medication and medication hidden in her food with the purpose of killing her. She presents a depressed mood, thoughts of death and worthlessness. No alterations of perception, such as olfactory or gustatory, were found. The interview with the informant (daughter) also revels alterations in the sleep/awake cycle as well as minor episodes of amnesia in the last year without compromising the autonomy of the patient. She has a history of psychiatric appointments lasting 6 years from 93 to 99 years old with the diagnose of dysthymia but the only medication that remained, after being discharge, was quetiapine 25mg in SOS. The physical examination as well as the complementary exams excluded infection or another medical cause for the symptomology, revelling only known pathologies, already medicated, more precisely hypertension, atrial flutter and angina pectoris.

During the inpatient treatment she was medicated with minimal doses of risperidone (0,5mg) and sertraline (25mg), with rapid improvement of her clinical condition with remission of the persecutory delusions, regularization of sleep and mood improvement, eventually getting discharged willingly to go back to her house. Conclusions: Despite the great prevalence of behaviour alterations in older people being in the context of dementia and delirium, it is always important to keep in mind that presenting a first episode of psychotic illness at an advanced age is not impossible. Taking the previous statement in consideration, those cases must be correctly diagnosed and treated. Regarding the treatment it is advisable to strictly follow the recommendations to start low and go slow as this

Classification of first-episode psychosis in a large cohort of patients using support vector machine and multiple kernel learning techniques

Using Machine Learning and Structural Neuroimaging to Detect First Episode Psychosis: Reconsidering the Evidence

Prediction Models of Functional Outcomes for Individuals in the Clinical High-Risk State for Psychosis or With Recent-Onset Depression